English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Our objective was to evaluate the biodistribution, kinetics, and radiation dosimetry of 64 CuCl 2 in humans and to assess the ability of 64 CuCl 2 PET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: We prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent 64 CuCl 2 PET/CT, 18 F-choline PET/CT, and multiparametric MRI within 15 d of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated. Histopathology, when available; clinical or laboratory response; and multidisciplinary follow-up were used to confirm the site of disease. In parallel, biodistribution, kinetics of the lesions, and radiation dosimetry of 64 CuCl 2 were evaluated. Results: From a dosimetric point of view, an administered dose of 200 MBq for 64 CuCl 2 translated into a 5.7-mSv effective dose. Unlike 18 F-choline, 64 CuCl 2 was not excreted or accumulated in the urinary tract, thus allowing thorough pelvic exploration. The maximum 64 CuCl 2 uptake at the sites of PCa relapse was observed 1 h after tracer injection. In our cohort, 64 CuCl 2 PET/CT proved positive in 41 of 50 patients, with an overall DR of 82%. The DRs of 18 F-choline PET/CT and multiparametric MRI were 56% and 74%, respectively. The difference between the DRs of 64 CuCl 2 PET/CT and 18 F-choline PET/CT was statistically significant ( P &lt; 0.001). Interestingly, on considering prostate-specific antigen (PSA) value, 64 CuCl 2 PET/CT had a higher DR than 18 F-choline PET/CT in patients with a PSA of less than 1 ng/mL. Conclusion: The biodistribution of 64 CuCl 2 is more suitable than that of 18 F-choline for exploring the pelvis and prostatic bed. The 64 CuCl 2 effective dose is like those of other established PET tracers. In patients with biochemical relapse and a low PSA level, 64 CuCl 2 PET/CT shows a significantly higher DR than 18 F-choline PET/CT.

64CuCl2 PET/CT in Prostate Cancer Relapse

⁶⁴CuCl₂ PET/CT in Prostate Cancer Relapse